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are not associated with CCSVI in MS
Carmela Leone1, Emanuele D’Amico1, Sabina Cilia1, Alessandra Nicoletti1, Luigi Di Pino2 and Francesco Patti1*Abstract
Background: We investigated the association between chronic cerebrospinal venous insufficiency (CCSVI) and
cognitive impairment (CI) in multiple sclerosis (MS). Moreover, we evaluated the association between CCSVI and
other frequent self-reported MS symptoms.
Methods: We looked at the presence of CI in incident MS patients with CCVSI in a population-based cohort of Catania,
Italy. All subjects were group-matched by age, sex, disease duration and EDSS score with MS patients without CCSVI,
serving as controls. CI was assessed with the Brief Repeatable Battery (BRB) and the Stroop Test (ST) and it was defined by
the presence of at least three impaired tests. Fatigue and depressive symptoms were assessed with Fatigue Severity Scale
(FSS) and Hamilton Depressive Rating Scale (HDRS), respectively. Bladder and sexual symptoms were assessed with the
respective items of the Italian version of Guy's Neurological Disability Scale (GNDS). Quality of life was evaluated with
Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54).
Results: Out of 61 MS patients enrolled in the study, 27 were CCSVI positive and 34 were CCSVI negative. Of them, 43
were women (70.5%); the mean age was 43.9 ± 11.8 years; the mean disease duration was 159.7 ± 113.7 months; mean
EDSS was 3.0 ± 2.6. Of them, 36 (59.0%) were classified relapsing-remitting (RR), 12 (19.7%) secondary progressive (SP),
seven (11.5%) primary progressive (PP) and six (9.3%) Clinically Isolated Syndrome (CIS). Overall, CI was detected in 29/61
(47.5%) MS patients; particularly 13/27 (48.1%) in the CCSVI positive group and 16/34 (47.0%) in the CCSVI negative group.
Presence of CCSVI was not significantly associated with the presence of CI (OR 1.04; 95% CI 0.37-2.87; p-value = 0.9). Not
significant differences were found between the two groups regarding the other MS symptoms investigated.
Conclusions: Our findings suggest a lack of association between CCSVI and CI in MS patients. Fatigue, depressive,
bladder/sexual symptoms and self-reported quality of life are not associated with CCSVI.Background
Multiple sclerosis (MS) is an inflammatory-mediated de-
myelinating disease of the Central Nervous System (CNS),
characterized also by axonal damage in the brain and spinal
cord [1] and cortical lesions [2]; its pathogenesis is still un-
known, but it is most likely caused by a complex interplay
between polygenetic and environmental factors [3,4].
Recently, it was hypothesized that extra-cranial venous
abnormalities, named chronic cerebrospinal venous in-
sufficiency (CCSVI), might play a role in the pathogen-
esis of MS [5,6]. CCSVI has been described to interfere
with venous drainage from the CNS, which contributes
to the development and progression of MS; moreover,* Correspondence: patti@unict.it
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reproduction in any medium, provided the orwhen the stenotic lesions in the internal jugular and azy-
gos veins were treated with balloon angioplasty, rapid
and often dramatic symptomatic improvement in many
patients has been reported [7]. However, a number of
studies have showed controversial data (ranges from 0%
to 100%) about the frequency of CCSVI in MS patients
so far see in review, [8]. Recently, our group found that
CCSVI was present in 18.9% of MS patients [9], but one
more recent study did not find any association between
CCSVI and MS [10]. Although several studies have re-
cently evaluated the effects of CCSVI endovascular treat-
ment on subjective aspects of MS, such as fatigue,
patients clinical status and their quality-of-life [7,11-14],
to date no studies have investigated the possibility of an
association between CCSVI and symptoms of MS.
MS determines not only motor symptoms and signs
which are responsible for the so-called physical disability,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reported symptoms and signs so-called “invisible symp-
toms” [15]. Among them, in recent years, much attention
has been focused on bladder and sexual disorders, visual
symptoms, fatigue, pain, depression and anxiety, and espe-
cially, on cognitive disorders.
Cognitive impairment (CI) is a well-recognized symp-
tom of MS, occurring in about half of all patients; it is a
disabling symptom which contributes to the poor quality
of life in MS patients [16]. CI is a common finding in
brain vascular diseases also; however, because of evolv-
ing definitional criteria, the precise frequency of vascular
CI is difficult to assess [17]. The cerebral flow reduction,
which is a key feature of brain vascular diseases, has
been recently investigated in MS [18]. A widespread
cerebral hypo perfusion seen in MS [18], leading to brain
atrophy, could be the result of the venous outflow ob-
structions secondary to CCSVI [19].
We aimed to investigate whether CCSVI may be asso-
ciated with CI in MS patients. Bearing in mind that CI
could be a direct effect of MS or an effect of the cere-
brovascular hypo perfusion, we sought to investigate the
presence of a possible association between CCSVI and
CI in MS patients.
Methods
Ethics statement
The study was approved by the two different local ethical
committees (Azienda Universitaria-Ospedaliera Policlinico
Vittorio Emanuele di Catania and Ethical Committe of
the Azienda Sanitaria Locale 3 of Catania). Patients and
controls were enrolled after they had signed the informed
consent.
Study population
We recently carried out a population-based case–control
study to evaluate the possible association between MS and
CCSVI [9]. Briefly, from 1 January 1975 to 31 December
2004, 367 MS patients resident in the study area had had
the onset of disease [20-22]. Presence of CCSVI was eval-
uated in 148 MS patients randomly selected from this well
defined incident-cohort and in 20 patients affected by CIS.
All MS subjects enrolled in the study had fulfilled Poser
criteria for Clinically Defined MS [23]. All CIS subjects
enrolled had fulfilled McDonald criteria [24]. CCSVI, de-
fined according to the Zamboni’s criteria, was found in 28
of the 148 MS patients, and in 2 of the CIS patients. De-
tails are described elsewhere [9]. To evaluate the possible
association between CI and CCSVI we enrolled in the
present study, all MS and CIS patients who fulfilled the
diagnostic criteria for CCSVI identified in the previous
population-based case–control study [9]. Control subjects
were selected among the 130 patients without CCSVI and
were “frequency matched” by age (± five years), sex, meanEDSS, mean disease duration and disease course. Exclusion
criteria were the presence of known vascular malfor-
mations and mental illness (history of psychiatric disorders
including suicidal ideation or any episode of clinically se-
vere depression diagnosed by DSMIV [25]), history of
chronic drug or alcohol abuse prior to neuropsychological
(NPS) examination, any traumatic history occurring within
3 months prior to NPS examination and pregnancy. Pa-
tients who had experienced a MS relapse within the 50 days
prior to study entry were excluded from the study.
Clinical and exposure assessment
As described elsewhere, the presence of CCSVI was de-
fined as the presence of at least two out of the follow
five parameters [5]:
I. Reflux in the IJV and/or VVs in sitting and supine
posture;
II. Reflux in the DCVs;
III. High-resolution B-mode evidence of IJV stenosis;
IV. Flow not Doppler detectable in the IJVs and/or VVs;
V. Reverted postural control of the main cerebral
venous outflow pathways.
ECD and TCC ultrasonographies were performed by
an experienced vascular sonographer who attended a
course on CCSVI at the University of Ferrara in 2011
(supervisor Dr Zamboni, who first described this modality
of CCSVI assessment in MS). All enrolled patients under-
went a complete physical examination, including blood
pressure measurement and detailed medical history; they
also underwent a CT angiography to evaluate other pos-
sible causes of cerebrovascular disease.
NPS assessment
All neurological examinations were performed by trained
and certified examining neurologist [Neurostatus, 2006;
available at http://www.neurostatus.net]; for each patient
the Expanded Disability Status Scale (EDSS) [26] was
recorded the same day of NPS assessment, which was
obtained within two weeks from Echo Color Doppler
examination.
The NPS assessments included Rao’s Brief Repeatable
Battery (BRB) [27,28] and the Stroop Colour-Word Task
(ST) [29] for cognitive domains. All patients underwent
cognitive testing for the first time and took the same
form of the BRB test (Form A). The BRB incorporates
tests of verbal memory acquisition and delayed recall
(Selective Reminding Test, SRT) [30], visual memory ac-
quisition and delayed recall (10/36 Spatial Recall Test,
SPART) [31], attention, concentration, and speed of in-
formation processing (Paced Auditory Serial Addition
Test, PASAT [32]; Symbol Digit Modalities Test, SDMT)
[33], and verbal fluency on semantic stimulus (Word List
Table 1 Baseline demographic and clinical characteristics
of study sample
CCSVI- CCSVI+ p-value
N° (%) 34 27 0.3
W/M (%) 24 (70.5) 19 (70.3) 1.0
Age (mean ± SD) 42.3 ± 12.3 46.1 ± 11.1 0.3
EDSS (mean ± SD) 3.1 ± 2.8 3.0 ± 2.3 1.0
Disease Duration (years; mean ± SD) 13 ± 9.9 13.7 ± 8.8 0.6
Mean Education (years; mean ± SD) 11.9 ± 3.9 12.1 ± 4.6 0.7
RR (%) 19 (55.9) 17 (63.0) 0.5
SP (%) 9 (26.5) 3 (11.1) 0.2
PP (%) 2 (5.9) 5 (18.5) 0.2
CIS (%) 4 (11.8) 2 (7.4) 0.7






CIS clinically isolated syndrome.
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in the following order: SRT Long Term Storage (LTS,
SRT Consistent Long-Term Retrieval (SRT-CLTR), SPART,
SDMT, PASAT 3′, PASAT 2′, SRT-Delayed (SRT-D),
SPART-Delayed (SPART-D), WLG-A and ST. All the pa-
tients were examined by the same neuropsychologist in
order to uniform criteria of administration, data recording
and scoring procedures. In order to guarantee the blinding
of the neuropsychologist, we instructed subjects not to re-
veal their CCSVI status during NPS examination. Failure
on a test was defined using the available normative data
for the Italian population, considering the fifth percentile
of the Italian population performance on each evaluation
as the cut-off point for calculating the number of failed
tests of the BRB; for the ST we considered the ninety-fifth
percentile [27]. Cut-off points were applied to the scores
adjusted by age and education [27].
Patient intelligence quotient (IQ) was determined before
the NPS assessment by administering the Brief Intelligence
Test (BIT) [35]. The BIT is based on the correlation be-
tween general intelligence and reading ability. The test
comprises a reading skill test of 54 words with either regu-
lar or irregular emphasis (accent) [35,36].
Quality of life (QoL) was assessed by the MSQoL-54
questionnaire [37], depressive symptoms by the Hamilton
Depression Rating Scale (HDRS) [38], fatigue by the Fa-
tigue Severity Scale (FSS) [39], bladder and sexual symp-
toms by the respective items of the Italian version of
GNDS [40]. These tests were self-administered one-three
days before NPS testing.Table 2 Distribution of venous hemodynamic criteria
among CCSVI positive patients
Number of CCSVI positive patients (%)
Criterion III 19 (28.8%)
Criterion II 16 (24.2%)
Criterion I 15 (22.7%)
Criterion V 15 (22.7%)
Criterion IV 1 (1.5%)
Criterion I = Reflux in the IJVs and/or VVs in sitting and supine posture.
Criterion II = Reflux in the DCVs.
Criterion III = High-resolution B-mode evidence of proximal IJV stenoses.
Criterion IV = Flow not Doppler detectable in the IJVs and/or VVs.
Criterion V = Reverted postural control of the main cerebral venous outflow
Pathway (Δ CSA).
N number.
IJVs internal jugular veins.
VVs vertebral veins.
DCVs deep cerebral veins.Statistical analysis
Data were analyzed using STATA 10.0 software packages
[41]. Data were double entered into the database. Data
cleaning was also performed before the data analysis
considering both range and consistence checks. Quanti-
tative variables were described using mean and standard
deviation (mean ± SD). Means and proportions were
assessed by t-test and Chi-square test respectively. In case
of not a normal distribution appropriate non-parametric
tests were performed. Unconditional logistic regression
analysis was performed and for each study variable, we cal-
culated OR, 95% CI, and p value (two-tailed test, p = 0.05).
Parameters associated with the outcome at the univariate
analysis with a threshold of p = 0.10 were included in the
model. The model was manually constructed using the
Likelihood Ratio Test (LRT) to compare the log-likelihood
of the model with and without a specific variable.
Multiple linear regression analysis was used to test
whether demographic and clinical characteristics including
CCSVI, can predict the cognitive outcome. The number of
failed subtests was selected as the variable representing the
extent of cognitive decline.Whenever variables were dichotomized or polycho-
tomized, the cut-offs were derived from the pooled dis-
tribution of cases and control subjects (e.g., using the
median, tertiles, or quartiles).Results
Out of the 30 patients (28 MS and 2 CIS) CCSVI positive
identified in the previous population-based case–control
study, 27 (25 MS and two CIS) were enrolled in the study.
Out of the 138 MS and CIS patients without CCSVI, iden-
tified in the previous study, using a frequency matching,
34 similar in terms of age (± 5 years), sex, mean EDSS,
mean disease duration and disease course were enrolled in
the study as control group.
Demographic and clinical characteristics of patients
with and without CCSVI are reported in Table 1.
Table 3 Multiple linear regression analysis: predictors of
cognitive dysfunction
Outcome Predictors Coefficient p-value
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Figure 1 (a) Frequency distribution of impaired NPS tests among cog
NPS tests among CCSVI + and CCSVI- MS pts.
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patients are detailed in Table 2.
CI was present in 13/27 CCSVI positive MS-patients
and in 16/34 CCSVI negative MS-patients (48.1% and
47.0%, respectively). At univariate analysis presence of
CCSVI was not associated with presence of CI (OR 1.04;
95% CI 0.37-2.87; p-value = 0.9). A close association (OR
0.90; 95% CI 0.23-3.53; p-value = 0.8) was found performing
a multivariate analysis and adjusting by age sex and EDSS
considered as a priori confounders and included in the
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increasing age (p-value 0.01), followed by higher EDSS
(p-value 0.08), proved to be positively correlated with the
severity of cognitive dysfunction defined as the number of
test failed as shown in Table 3.
The most frequently impaired tests found in CI pa-
tients were SDMT, 3′ PASAT and 2′ PASAT, SRT-D and
ST (see Figure 1a). For the cognitive profile, no signifi-
cant difference was found between the two groups (see
Figure 1b). Regarding the self-reported measures of fa-
tigue, depressive symptoms, bladder/sexual disturbances
and quality of life not significant differences between
CCSVI positive and CCSVI negative patients were found
(see Table 4).
Discussion
Our study, performed in a well-defined MS population,
showed that CI was not associated with CCSVI. We
found about the same prevalence of CI between CCSVI-
positive (48.1%) and CCSVI-negative patients (47.0%).
Moreover, a similar prevalence of other frequent reported
MS-symptoms, such as fatigue, depression and bladder/
sexual disturbances, was found between the two groups.
These findings suggest that CCSVI is not correlated to the
cognitive status and other MS symptoms investigated, at
least in our well-selected MS population.
Our study is the first evaluating the possible associ-
ation between CCSVI and one of the most disabling MS
symptoms such as CI. In the few years, a number of
studies were carried out to evaluate the possible associ-
ation between CCSVI and MS; most of them reported
higher frequency of CCSVI among MS patients and sug-
gested a possible pathogenic role of CCSVI in determin-
ing specific symptoms and signs [5,8]. Although our
recent population-based study [9] demonstrated that
CCSVI was associated with MS, especially with progres-
sive forms of the disease, there is no agreement about
the exact frequency of CCSVI in MS, its putative patho-
genic role and its contribution, if any, on MS symptomsTable 4 Self-report MS symptoms measures at the time of ev
CCSVI-
FSS (mean ± SD) 3.7 ± 1.7
HDRS (mean ± SD) 5.0 ± 3.7
Bladder symptoms GNDS (mean ± SD) 1 ± 1.4
Sexual symptoms GNDS (mean ± SD) 1 ± 1.8
MSQOL-54-PHCS (mean ± SD) 65.3 ± 21.4
MSQOL-54-MHCS (mean ± SD) 64.2 ± 20.4
Data are given as means ± standard deviations.
FSS Fatigue Severity Scale.
HDRS Hamilton depression Rating Scale.
GNDS Guy’s Neurological Disability Scale.
MSQOL-54 Multiple Sclerosis Quality of Life-54.
PHCS Physical Health Composite Score.
MHCS Mental Health Composite Score.[5,8,42-45]. CI is one of the most common and disabling
symptom of MS, occurring in about half of all MS patients.
Literature data show that the most common cognitive def-
icits in MS patients are memory and speed of information
processing, concentration and executive functions [16,46].
However, the mechanisms underlying CI in MS has not
been fully elucidated. Several cross sectional studies dem-
onstrated that the pathogenesis of CI in MS patients might
not depend just on the extent and severity of the patho-
logical process in the brain lesions, but also on the patho-
logical changes affecting the normal appearing brain tissue
[47-49]. Considering that, we could take into account the
possible vascular hypothesis as a possible contribute to the
presence of a spread or regional brain atrophy, which is
one of the strongest factor correlated with the CI in MS
[50-52]. Impaired cerebral perfusion seems to be related to
CI [18] and a widespread cerebral hypo perfusion in MS,
described as a potential cause of brain atrophy [50-52],
could be the result of the venous outflow obstructions as
seen in the CCSVI [19]. Although there is no strong evi-
dence suggesting that CCSVI is a cause of MS, there is
some evidence that a slower cerebral venous flow in pa-
tients with MS might be secondary to the reduced cerebral
blood flow [19].
Our results do not support the hypothesis that CCSVI
might be responsible for the appearance or worsening of
CI in MS.
This study represents the first population-based case
control-study looking at the possible association between
CCSVI and CI in MS.
The population-based design represents the main
strength of our study reducing the risk of a possible se-
lection bias. Nevertheless such design has led to a small
study size allowing us to enrol just a limited number of
cases and controls. Consequently the lack of association
between CCSVI and CI in MS patients could be due to a
lack of power (type II error). Furthermore the retro-
spective nature of the study did not allow us to establish
the exact sequence of the events. In order to exclude aaluation
CCSVI+ p-value
3.0 ± 1.8 0.7
6.7 ± 4.6 0.7
0.8 ± 1.0 0.7
0.96 ± 1.4 0.6
70.3 ± 17.2 0.2
67.5 ± 19.6 0.2
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NPS performance, we evaluated subjective fatigue and
depressive symptoms, excluding that these symptoms
could be correlated with CCSVI.
CI was detected by a single trained Neuropsychologist
in order to avoid any inter-rater disagreement.
Although the role of CCSVI in MS pathology is still
unknown and the previous evidence are controversial so
far, further prospective studies are needed to withdraw
the hypothesis that CCSVI might play a role in deter-
mining CI or other invisible symptoms in MS.
Conclusions
Our findings suggest a lack of association between the
presence of CCSVI with CI and others “invisible symp-
toms” in patients with MS.
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